LION (Phase III Trial): Lymphadenectomy for LN-Negative Advanced Ovarian Cancer Following Complete Resection

June 2-6, 2017; Chicago, Illinois
In the phase III LION trial, systemic pelvic and para-aortic lymphadenectomy offered no survival benefit and increased postoperative morbidity and mortality in patients with advanced ovarian cancer, macroscopic complete resection, and clinically/radiographically negative lymph nodes.
Format: Microsoft PowerPoint (.ppt)
File Size: 581 KB
Released: June 5, 2017

Acknowledgements

Supported by educational grants by
AbbVie
Amgen
AstraZeneca
Celgene Corporation
Genentech
Halozyme Therapeutics
Incyte
Merck & Co., Inc.

Related Content

Clinical commentary with Shannon N. Westin, MD, MPH, discussing patients’ considerations affecting treatment choices, from Clinical Care Options (CCO)

Shannon N. Westin, MD, MPH Released: September 23, 2021

Podcast episode with expert insights on practice changing data from virtual IGCS 2021 for endometrial, ovarian, cervical cancers, from Clinical Care Options (CCO)

person default Alexandra Leary, MD, PhD Domenica Lorusso, MD, PhD Released: September 21, 2021

Virtual presentation by Shannon N. Westin, MD, MPH, on improving health equity for patients with endometrial cancer, from Clinical Care Options (CCO)

Shannon N. Westin, MD, MPH Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: September 17, 2021 Expired: September 16, 2022

Downloadable slideset updated with highlights of key gynecologic oncology studies presented at conferences throughout 2021, from Clinical Care Options (CCO)

Jubilee Brown, MD Melissa M. Hardesty, MD, MPH person default Alexandra Leary, MD, PhD Domenica Lorusso, MD, PhD Ursula Matulonis, MD David Scott Miller, MD, FACOG, FACS Released: September 15, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue